ClinConnect ClinConnect Logo
Search / Trial NCT02346292

Observational Multicenter Non-interventional Study on COPD Patients Treatment Strategies at the Time of Hospital Discharge and Within 12 Months of Follow-up on an Outpatient Primary Care Basement

Launched by ASTRAZENECA · Jan 26, 2015

Trial Information

Current as of May 14, 2025

Completed

Keywords

Copd Spirometry Severe And Very Severe Copd Copd Exacerbations Therapy Schemes Therapy Changes

ClinConnect Summary

The study is an observational multicenter descriptive study. It is planned to enroll approximately 1000 subjects with severe and very severe COPD hospitalized for the reason of COPD exacerbation into departments of pulmonology or therapy. The study will be conducted in approximately 20-25 institutions of treatment and prevention in Russian Federation and will include about 50 to 60 subject at each clinical site.

This is an observational study, so there is no treatment protocol or subjects' management recommendations required. The study subjects receive medical treatment according to the ro...

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Signed informed consent . Men and women at least 40 years old, with smoking history more than 10 pack-years.
  • Hospitalization for the reason of COPD exacerbation (exacerbation defined as acute condition, different from typical fluctuations of general condition and requiring change of therapy).
  • Diagnosis of severe or very severe COPD based on final spirometry (performed in a standardized manner using salbutamol 400 mg), or history of diagnosis of severe or very severe COPD based on spirometry performed during 6 months before the hospitalization.
  • Exclusion Criteria:
  • Participation in any interventional study.
  • Concomitant respiratory diseases, i.e. confirmed or suspected malignancy or any other serious condition, including lung tumor, lung fibrosis, interstitial lung disease, tuberculosis, sarcoidosis.
  • Patient is unable or unwilling to complete questionnaires, unable to understand study procedures, or other reasons which, in the investigator's opinion, could affect study procedures performance.

About Astrazeneca

AstraZeneca is a global biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative medicines across various therapeutic areas, including oncology, cardiovascular, respiratory, and autoimmune diseases. With a strong commitment to scientific research and patient-centric solutions, AstraZeneca leverages cutting-edge technology and a robust pipeline to address unmet medical needs. The company collaborates with healthcare professionals, academic institutions, and other organizations to advance clinical trials and deliver transformative therapies, aiming to improve health outcomes and enhance the quality of life for patients worldwide.

Locations

St.Petersburg, , Russian Federation

Ekaterinburg, , Russian Federation

Kazan, , Russian Federation

Krasnodar, , Russian Federation

Yaroslavl, , Russian Federation

Rostov On Don, , Russian Federation

Smolensk, , Russian Federation

Kemerovo, , Russian Federation

Krasnoyarsk, , Russian Federation

Novosibirsk, , Russian Federation

Ryazan, , Russian Federation

Moscow, , Russian Federation

Barnaul, , Russian Federation

Omsk, , Russian Federation

Izhevsk, , Russian Federation

Ufa, , Russian Federation

Chelyabinsk, , Russian Federation

Kursk, , Russian Federation

Petrozavodsk, , Russian Federation

Chita, , Russian Federation

Yakutsk, , Russian Federation

Orel, , Russian Federation

Kirov, , Russian Federation

Seversk, , Russian Federation

Gatchina, , Russian Federation

Voronez, , Russian Federation

Blagoveshchensk, , Russian Federation

Cherepovets, , Russian Federation

Naberezhnye Chelny, , Russian Federation

Novokuznetsk, , Russian Federation

Patients applied

0 patients applied

Trial Officials

Alexander Bedenkov, Medical Director

Study Director

AstraZeneca

Sergey Avdeev, MD, PHD

Principal Investigator

Federal State Institution "Scientific Research Institute of Pulmonology" FMBA of Russia

Andrey Belevsky, PHD

Principal Investigator

Federal State Institution "Scientific Research Institute of Pulmonology" FMBA of Russia

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials